Analysts Set Expectations for INKT FY2030 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of MiNK Therapeutics in a research report issued on Wednesday, April 1st. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of $1.31 for the year. HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.14.

Separately, Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Stock Up 0.4%

INKT opened at $10.57 on Thursday. The firm’s fifty day simple moving average is $10.92 and its two-hundred day simple moving average is $12.23. MiNK Therapeutics has a 52-week low of $6.34 and a 52-week high of $76.00. The company has a market cap of $49.57 million, a price-to-earnings ratio of -3.56 and a beta of 0.35.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC increased its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the quarter. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell?to?cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor?associated macrophages and boost T cell–mediated tumor clearance.